The dark side of SARS-CoV-2 rapid antigen testing: screening asymptomatic patients.

COVID-19 diagnostic testing SARS-CoV-2 emergency ward health plan implementation rapid antigen test

Journal

New microbes and new infections
ISSN: 2052-2975
Titre abrégé: New Microbes New Infect
Pays: England
ID NLM: 101624750

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 29 04 2021
accepted: 09 05 2021
pubmed: 20 5 2021
medline: 20 5 2021
entrez: 19 5 2021
Statut: ppublish

Résumé

Several reports showed SARS-CoV-2 rapid antigen tests (RATs) performances among COVID-19 symptomatic subjects in outpatient settings during periods of highest incidence of infections and high rates of hospital admissions, but few data are present for asymptomatic patients. We investigated the role of RATs in an emergency department, as a novel screening tool before admission for COVID-19 asymptomatic patients. A total of 116 patients were screened on admission in a 250-bed community hospital in Morges, Switzerland. RAT detected 2/7 RT-PCR-positive patients and delivered two false-positive results. These data suggest the non-fiability of RATs screening in this clinical scenario.

Identifiants

pubmed: 34007453
doi: 10.1016/j.nmni.2021.100899
pii: S2052-2975(21)00063-9
pmc: PMC8119292
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100899

Informations de copyright

© 2021 The Author(s).

Références

Microorganisms. 2021 Apr 10;9(4):
pubmed: 33920307
J Infect. 2021 Mar;82(3):e14-e16
pubmed: 33347944
Pathog Dis. 2020 Nov 11;78(8):
pubmed: 33030200
Clin Microbiol Infect. 2020 Sep;26(9):1178-1182
pubmed: 32593741
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33139420
Biomarkers. 2021 May;26(3):213-220
pubmed: 33455451

Auteurs

G Caruana (G)

Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Switzerland.

L-L Lebrun (LL)

Patients Safety Program, Ensemble Hospitalier de la Côte (EHC), Morges, Switzerland.

O Aebischer (O)

Patients Safety Program, Ensemble Hospitalier de la Côte (EHC), Morges, Switzerland.

O Opota (O)

Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Switzerland.

L Urbano (L)

Patients Safety Program, Ensemble Hospitalier de la Côte (EHC), Morges, Switzerland.

M de Rham (M)

CoVID-19 Task Force Direction, Ensemble Hospitalier de la Côte (EHC), Morges, Switzerland.

O Marchetti (O)

Patients Safety Program, Ensemble Hospitalier de la Côte (EHC), Morges, Switzerland.

G Greub (G)

Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Switzerland.
Department of Medicine, Infectious Diseases Division, Lausanne University Hospital, Lausanne, Switzerland.

Classifications MeSH